“Congress should preserve the 340B Drug Pricing Program and protect patients and communities,” writes AHA Executive Vice President Tom Nickels in an AHA Stat blog post. He notes, “Every day, we see stories about the exorbitant costs of prescription drugs and the serious challenges they pose for individuals and the entire health care system. One program that has a 25-year track record of improving access to medications and health care services for people in vulnerable communities is the 340B program.” The blog post highlights examples of how hospitals in Florida, California and Vermont are using savings from the 340B program to fund medications for patients with no ability to pay and improve access to care for vulnerable populations. For more on the 340B program, see the AHA video. 

Headline
The Centers for Medicare & Medicaid Services Nov. 5 published a final rule to codify the Medicare Drug Price Negotiation Program beginning in 2029. The…
Headline
The estimated average monthly premium for Medicare Part D stand-alone prescription drug plans is $51 for 2027, a 50% increase from $34 in 2026, for enrollees…
Headline
The AHA Oct. 27 submitted comments on the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future of 340B…
Headline
In this conversation, Brent Davis, CEO of the primary health division at AdventHealth, shares how improved patient access, coordinated care teams, virtual care…
Headline
The U.S. District Court for the District of Maine should deny motions by several drug companies and Pharmaceutical Research and Manufacturers of America to…
Headline
The Centers for Medicare & Medicaid Services released a proposed rule Oct. 16 seeking to codify regulations that will improve the accuracy of Medicare…